Although improving ACh availability clearly shows improvements in AD symptoms, AChE inhibitors are nonselective in nature, which renders a myriad of dose-related adverse effects – such as gastrointestinal disturbances and bronchoconstriction [8]. The gene discussed is ACHE; the disease is Alzheimer disease.